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leading to the conclusion that other neurotransmitter path-
ways, above and beyond serotoninergic ones, can play a role in 
emergence of this rare and unique phenomenon.
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Abstract
Objectives: Although single clinical predictors have repeatedly 
been associated with TRD (treatment resistant depression), they 
have not proven sufficient for predicting treatment outcome1. 
Thus, attention shifted to interaction-based models but only 
few multivariate investigations have been performed in TRD so 
far2. Using the data pool of the Group for the Study of Treatment-
Resistant-Depression (GSRD) and a machine learning algorithm 
we intended to draw new insights and back up previous results 
featuring a set of 66 clinical and demographical predictors for 
treatment outcome.
Methods: 415 patients recruited between 2011 and 2015 in 11 
participating centers showed full availability for all 66 predic-
tors. Treatment response was defined by MADRS-score below 22 
and a reduction of 50% or more. A  score higher than 21 after 
at least two antidepressant trials of adequat dosage and length 
was considered as treatment resistance. After generating impor-
tance values for all predictors the prediction algorithm was 
trained in a sample of 385 patients. Subsequently, prediction 
was performed in a sample of 30 new patients not featured in 
the model generation.
Results: The accuracy for predicting treatment outcome in TRD 
was at 0.75 using all 66 predictors. Importance measurement 
revealed chronicity, i.e. full or partial intraepisodic recovery or 
chronic MDD, number of depressive episodes, age of first and 
last lifetime depressive episode, total time of hospitalization, 
education and occupation status, suicidal risk, marital status 
and number of children and cigarettes smoked per day as the 
most useful predictors.
Conclusion: Exploiting a machine-learning algorithm, we scored 
an accuracy of 0.75 for treatment outcome using a sample of 415 
patients. Reaching a probability of 83.4% for a correct prediction 
for treatment resistance and 66.6% for response we exceeded 
the predictive capabilities of clinicians. Thus, these results 
strengthen our previous data mining approaches and suggest 
keeping the focus on interaction-based statistical approaches3.
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Abstract
Objectives: There is considerable evidence that disturbances in 
neurotransmitter systems contribute to the pathophysiology of 
depression. Brain-derived neurotrophic factor (BDNF) is involved 
in the pathophysiology of depression, and in the mechanism of 
action of antidepressant medications. The mature form of BDNF 
is derived from proBDNF through tissue type plasminogen acti-
vator (tPA) and the plasminogen system in the brain. Therefore, 
tPA might be involved in the development of major depressive 
disorder (MDD) and its response to antidepressant treatment. 
Mirtazapine acts as an antagonist of the adrenergic alpha 1, 2 
and serotonin receptors. The present study determined the rela-
tionship between the Alu insertion/deletion (I/D) polymorphism 
on the tPA gene and the clinical outcome of mirtazapine treat-
ment in 422 Korean MDD patients.
Methods: 422 patients were enrolled in this study, and symp-
toms were evaluated by 21-item Hamilton Depression Rating 
scale. After 1, 2, 4, and 8 weeks of mirtazapine treatment, the 
association between Alu I/D polymorphism on tPA gene and 
remission/response outcomes were evaluated.
Results: The proportion of I/I homozygote in responders was 
higher than that in non-responders, whereas the proportion 
of D/D homozygote in responders was lower than that in non-
responders at 8 weeks of treatment (P=0.032, OR=1.57). The per-
cent decline of HAMD-21 score in I allele carriers was larger than 
that of D allele homozygotes at 2 and 8 weeks after mirtazapine 
treatment (P=0.035 and 0.007, respectively). I allele carriers were 
also significantly associated with remission at 8 weeks of treat-
ment (P=0.047, OR=2.2).
Conclusions: These results show that treatment response and 
remission to mirtazapine were significantly associated with Alu 
insertion/deletion polymorphism of the tPA gene. This suggests 
that Alu insertion/deletion polymorphism affects the therapeu-
tic action of mirtazapine in MDD, and may be a potential genetic 
marker for the prediction of therapeutic response to mirtazap-
ine treatment in patients with MDD.
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Abstract
Background: Previous research has reported evidence that 
patients with major depressive disorder (MDD) show anxiety 
symptoms and neurocognitive impairments. However, the influ-
ence of anxiety on neurocognitive function in MDD patients 
during antidepressant treatment is unclear.
Method: MDD patients (n=164) completed a 12-week, multi-
center, randomized trial assigned in a 1:1 ratio to either tian-
eptine or escitalopram. Changes of anxiety symptoms were 
assessed by the Hamilton Anxiety Rating Scale (HAM-A), and the 
Hamilton Depression Rating Scale (HAM-D), self-rated subjective 
cognitive impairment on memory and concentration, the Mini-
Mental Status Examination (MMSE), Continuous Performance 
Test (CPT), Verbal Learning Test (VLT), and Raven’s Progressive 
Matrices (RPM) were assessed every 4 weeks.
Results: During 12 weeks of treatment, decrease in the HAM-A 
score was significantly associated with improvement of subjec-
tive cognitive impairments on memory (p<0.001) and concen-
tration (p<0.001), and objective measures on delayed memory 
(p=0.006) and reasoning ability (p=0.002), after adjusting for 
covariates such as baseline HAM-A scores, time, sex, age, educa-
tion years and assigned medication using the Mixed effects and 
Generalized Estimated Equation model analysis. However, the 
other cognitive outcome variables, immediate memory, com-
mission error, and MMSE, which showed significant improve-
ment through 12-week study period, showed no significant 
association with improvement of anxiety.
Conclusion: Improvement of anxiety symptoms was signifi-
cantly associated with improvement in subjective and objective 
neurocognitive functions such as delayed memory and reason-
ing ability in elderly MDD patients during antidepressant treat-
ment, but not significantly associated with improvement of 
immediate memory and commission error.
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Abstract
 Prior cross-cultural studies have shown that Americans and East 
Asians differ with regards to the presentation of hypochondria-
sis symptoms. However, few studies have attempted to exam-
ine the prevalence and nature of hypochondriacal concerns 
among both American and East Asian patients with major 
depressive disorder (MDD). This study aimed to explore hypo-
chondriasis and its correlates, using the Hamilton Depression 
Rating Scale (HAM-D), among American and Korean MDD out-
patients of ages 18 and older. Consistent with previous cross-
cultural findings, Korean MDD patients exhibited significantly 
higher scores for hypochondriasis than Americans after con-
trolling for total HAM-D scores and demographic variables 
(p<0.0001), even though American patients had significantly 
higher total HAM-D scores (p<0.0001). Whereas hypochondria-
sis appeared to be common among Koreans regardless of age, 
years of education, and employment status, Americans showed 
an increased tendency for hypochondriasis with greater age, 
fewer years of education, and unemployment. Despite the 
cultural differences, multivariate logistic regression analyses 
revealed that hypochondriasis is significantly associated with 
somatic anxiety (Koreans AOR=2.14, 95%CI 1.31–3.52; Americans 
AOR=1.98, 95%CI 1.69–2.31), suicide (Koreans AOR=0.42, 95%CI 
0.24–0.74; Americans AOR=0.81, 95%CI 0.67–0.98), middle insom-
nia (Koreans AOR=1.95, 95%CI 1.18–3.23; Americans AOR=1.19, 
95%CI 1.01–1.41), and psychic anxiety (Koreans AOR=1.62, 95%CI 
1.00–2.61; Americans AOR=1.44, 95%CI 1.23–1.70) for both Korean 
and American MDD patients. Taken together, although hypo-
chondriasis is more prevalent among Koreans, both Korean 
and American MDD patients with hypochondriacal symptoms 
appear to display high levels of somatic anxiety regardless of 
whether they experience actual physical symptoms. These 
findings suggest that both cultural and personal factors play a 
role in the presentation of hypochondriasis symptoms among 
Korean and American patients with MDD.
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Abstract
Background: This aim of this study was to determine the impact 
of fluvoxamine, an inhibitor of CYP2C19, on the pharmacokinet-
ics of escitalopram, a substrate of CYP2C19.
Methods: Thirteen depressed patients initially received a 20 mg/
day dose of escitalopram alone. Subsequently, a 50 mg/day dose 
of fluvoxamine was administered due to the insufficient effi-
cacy of escitalopram. Plasma concentrations of escitalopram 
and desmethylescitalopram were quantified using HPLC before 
and after fluvoxamine co-administration. The QT and corrected 
QT (QTc) intervals were measured before and after fluvoxamine 
co-administration.
Results: Fluvoxamine significantly increased the plasma concen-
trations of escitalopram (72.3 ± 36.9 ng/ml versus 135.2 ± 79.7 ng/
ml, p<0.01) but not those of desmethylescitalopram (21.5 ± 7.0 ng/
ml versus 24.9 ± 12.0 ng/ml, ns). The ratios of desmethylescitalo-
pram to escitalopram were significantly increased during flu-
voxamine co-administration (0.37 ± 0.21 ng/ml versus 0.21 ± 0.10, 
p<0.01). The CYP2C19 genotype did not fully explain the degree 
of the change. Fluvoxamine co-administration did not change 
the QT or QTc intervals.
Conclusions: The results of the present study suggest that 
adjunctive treatment with fluvoxamine increases the concen-
tration of escitalopram. The QTc interval did not change in this 
condition.
